表紙
市場調査レポート

皮膚科治療薬市場の予測 (2015-2025年):主要企業の市場機会

Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies

発行 Visiongain Ltd 商品コード 233143
出版日 ページ情報 英文 310 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=142.08円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
皮膚科治療薬市場の予測 (2015-2025年):主要企業の市場機会 Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies
出版日: 2015年05月20日 ページ情報: 英文 310 Pages
概要

世界の皮膚科治療薬の市場は、過去数年にわたって戦略的買収や業界再編が続けられています。2015年の市場規模は245億ドルに達すると予測されており、皮膚科治療薬の需要の拡大、保険の適用範囲の拡大、生物学的製剤の成功、抗菌剤への耐性などが2025年に向けたさらなる成長を支援すると予測されています。

当レポートでは、世界の皮膚科治療薬の市場を調査し、皮膚医学の概要、一般的な皮膚疾患の種類と概要、疾患区分別の治療薬市場の最新動向、市場規模の推移と予測、主な治療薬のプロファイルおよび市場シェア、主要地域および国別の動向、開発パイプラインの動向、専門家へのインタビュー、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 皮膚科治療薬:イントロダクション

  • 医薬品産業:概要
  • 皮膚医学の概要
    • 皮膚、毛髪、爪の構造
    • 毛髪と爪
    • 汗腺と脂腺
    • 皮膚の構造
  • 一般的な皮膚疾患
  • 座瘡 (にきび):もっとも一般的な皮膚疾患
    • 疫学
    • 原因・病因
    • 治療
  • 皮膚炎:皮膚の炎症
    • アトピー性皮膚炎
    • 接触性皮膚炎 (CD)
    • 脂漏性皮膚炎
    • 貨幣状皮膚炎
    • 口囲皮膚炎
  • 乾癬:複雑な多因子性疾患
  • 酒さ:血管不安定性
  • 脱毛症:異常な抜け毛
  • 皮膚感染:深刻な健康上の脅威
    • 細菌性皮膚感染
    • 菌性皮膚感染
    • ウィルス性皮膚感染
  • 一般的な皮膚科治療
    • クリームや半固形乳剤
    • 軟膏
    • ローション
    • 液剤
    • 密封療法
    • 洗浄剤
    • 粉末や親水性ポリマー
    • 抗感染症剤
    • 抗炎症剤
  • 臨床試験のフェーズ
  • 皮膚科治療薬:本書での市場の定義

第3章 世界の皮膚科治療薬市場

  • 市場概要
  • 世界の皮膚科治療薬市場:カテゴリー区分
  • 市場実績
  • 市場予測
  • 部門別の市場シェアの予測

第4章 乾癬治療薬市場の分析・予測

  • 乾癬治療薬:生物製剤の成功
    • 主要製品
  • 市場動向・発展動向
  • 市場予測
  • 主な薬剤
  • Humira (アダリムマブ:Abbott)
  • Stelara (ウステキヌマブ:Johnson & Johnson)
  • Enbrel (エタネルセプト:Amgen・Pfizer・武田薬品工業)
  • Remicade (インフリキシマブ:Johnson & Johnson)
  • Daivobet (カルシポトリオール・ベタメサゾン:LEO Pharma)
  • Soriatane (アシトレチン:GSK)
  • その他
  • サマリー

第5章 皮膚感染治療薬市場の分析・予測

  • 皮膚感染治療薬:豊富な成長機会
    • 主要製品
  • 市場予測
  • 主な薬剤
  • Cubicin (ダプトマイシン:Cubist Pharmaceuticals)
  • Zyvox (リネゾリド:Pfizer)
  • Valtrex (バラシクロビル:GSK)
  • Canesten (クロトリマゾール:Bayer)
  • Lamisil (テルビナフィン:Novartis)
  • Bactroban (ムピロシン:GSK)
  • その他
  • サマリー

第6章 座瘡治療薬市場の分析・予測

  • 座瘡治療薬:多様化する市場
    • 主要製品
  • 近年の動向・発展動向
  • 市場予測
  • 主な薬剤
  • Solodyn (ミノサイクリン:Valeant)
  • Epiduo (アダパレン/過酸化ベンゾイル:Galderma/Nestle Skin Health)
  • Claravis (イソトレチノイン:Teva)
  • Aczone (ダプソン:Allergan)
  • Differin (アダパレン:Galderma/Nestle Skin Health)
  • Absorica/Epuris (CIPイソトレチノイン:Cipher/ Sun Pharma)
  • Ziana (トレチノイン・クリンダマイシン:Valeant)
  • Doryx (ドキシサイクリン塩酸塩:Actavis/ Mayne Pharma)
  • その他
  • サマリー

第7章 皮膚炎治療薬市場の分析・予測

  • 皮膚炎治療薬:ジェネリック薬の高い普及率
    • 主要製品
  • 市場予測
  • 主な薬剤
  • Bepanthen (デクスパンテノール:Bayer)
  • Protopic (タクロリムス:アステラス/Roche)
  • Elidel (ピメクロリムス:Meda AB/Valeant)
  • Elocon (フランカルボン酸モメタゾン:Merck & Co)
  • その他
  • サマリー

第8章 主要国市場の予測

  • 地域別市場
  • 主要国市場の予測
    • 市場シェアの変化の予測
  • 市場分析・予測:地域別
  • 米国
  • EU5カ国
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
  • 日本
  • 中国
  • インド
  • ブラジル
  • ロシア
  • メキシコ
  • その他

第9章 主要企業

第10章 R&Dパイプラインの予測

  • 開発中の革新的製品
  • 乾癬治療薬のパイプライン
  • 皮膚感染症治療薬のパイプライン
  • 座瘡治療薬のパイプライン
  • 皮膚炎治療薬のパイプライン
  • その他の治療薬のパイプライン

第11章 市場の定性分析

  • 市場への影響因子
  • SWOT分析
  • ポーターのファイブフォース分析

第12章 専門家の見解

第13章 総論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0047

Dermatological drugs - new study showing you trends, partnerships, and predicted revenues

Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:

  • Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:

  • Skin infection drugs market forecast 2015-2025
  • Dermatitis drugs market forecast 2015-2025
  • Acne drugs market forecast 2015-2025
  • Psoriasis drugs market forecast 2015-2025
  • Other dermatological drugs market forecast 2015-2025

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products

How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands:

  • Remicade
  • Humira
  • Claravis
  • Epiduo
  • Bepanthen
  • Solodyn
  • Enbrel
  • Protopic
  • Cubicin
  • Canesten

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?

Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.

In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.

  • US
  • China
  • Japan
  • Germany
  • India
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • Mexico
  • Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth

Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to visiongain's forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:

  • AbbVie
  • Galderma
  • GlaxoSmithKline
  • Johnson & Johnson
  • LEO Pharma
  • Pfizer

A company profile gives you the following information:

  • Revenue forecast for dermatological drugs from 2015 to 2025
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
  • Discussion of a company's activities and outlook

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities - assess innovation, trends and possibilities

What is happening in the R&D pipeline for dermatological treatments? You see developmental trends, gaining insight into each phase of the dermatology R&D pipeline for:

  • Acne pipeline drugs
  • Dermatitis pipeline drugs
  • Psoriasis pipeline drugs
  • Skin infections pipeline drugs
  • Other progress in dermatology

Our study also discusses these agents and technologies, among others:

  • Photodynamic therapy
  • Drug delivery
  • Novel small molecules
  • Oral drug candidates

What issues will affect the dermatological drugs market?

Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting dermatological treatments. You will find discussions, including qualitative analyses:

  • Pricing and reimbursement pressures created by government cost-cutting initiatives
  • Patient compliance and the advances in topical drug delivery
  • A strong R&D pipeline
  • Personalised dermatology and genomics
  • Consolidation among players in the market
  • Patent expiries and generic competition
  • The changing socio-economic conditions impacting dermatological drug demand
  • Demographic trends impacting demand for dermatological drugs

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape

How the Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies report helps you

In summary our 310 page report gives you the following knowledge:

  • Revenues to 2025 for the overall dermatological drugs market - discover the industry's prospects, finding promising areas for investments and revenues
  • Revenue forecasts to 2025 for four product categories (therapeutic classes) within dermatological drugs - discover forecasts for Psoriasis drugs, Dermatitis drugs, Acne drugs, Skin infection drugs, and Other dermatological drugs
  • Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
  • Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and dermatological drugs revenue forecast for 6 leading companies, including Pfizer, LEO Pharma, Johnson & Johnson, AbbVie, and GlaxoSmithKline
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • Opinions from our survey, seeing interviews with industry authorities
  • IP protection and generic drug competition - see what affects product revenue

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the dermatological drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Dermatological Drugs: Market Overview
  • 1.2. Global Dermatological Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. An Introduction To Dermatological Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
  • 2.2. An Introduction To Dermatology
    • 2.2.1. The Structural Lay-out Of The Skin, Hair, And Nails
    • 2.2.2. Hair And Nails
    • 2.2.3. Sweat And Sebaceous Glands
    • 2.2.4. Functions Of The Skin
  • 2.3. Common Skin Diseases
  • 2.4. Acne: The Most Common Skin Disease
    • 2.4.1. Acne: Epidemiology
    • 2.4.2. Acne: Causes And Pathogenesis
    • 2.4.3. Acne: Treatment
  • 2.5. Dermatitis: Inflammation Of The Skin
    • 2.5.1. Atopic Dermatitis
    • 2.5.2. Contact Dermatitis
    • 2.5.3. Seborrhoeic Dermatitis
    • 2.5.4. Nummular Dermatitis
    • 2.5.5. Perioral Dermatitis
  • 2.6. Psoriasis: A Complex Multi-factorial Disease
  • 2.7. Rosacea: Vascular Instability
  • 2.8. Alopecia: Excessive Shedding Of Hair
  • 2.9. Skin Infections: A Serious Healthcare Threat
    • 2.9.1. Bacterial Skin Infections
    • 2.9.2. Fungal Skin Infections
    • 2.9.3. Viral Skin Infections
  • 2.10. Common Skin Treatments
    • 2.10.1. Creams and Semisolid Emulsions
    • 2.10.2. Ointments
    • 2.10.3. Lotions
    • 2.10.4. Solutions
    • 2.10.5. Occlusive Therapy
    • 2.10.6. Cleansing Agents
    • 2.10.7. Powders and Hydrophilic Polymer
    • 2.10.8. Anti-Infective Agents
    • 2.10.9. Anti-Inflammatory Agents
  • 2.11. Phases Of Clinical Trials
  • 2.12. Dermatological Drugs: Market Definition In This Report

3. The Global Dermatological Drugs Market, 2015-2025

  • 3.1. The Global Dermatological Drugs Market: Market Overview
  • 3.2. Categorisation Of The Global Dermatological Drugs Market
  • 3.3. The Global Dermatological Drugs Market In 2014
  • 3.4. The Global Dermatological Drugs Market: Market Forecast 2015-2025
  • 3.5. Dermatological Drugs: Changing Market Shares By Sector 2015-2025

4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025

  • 4.1. Psoriasis Treatments: The Dominance Of Biologics
    • 4.1.1. Leading Products In The Psoriasis Drugs Market, 2014
  • 4.2. Psoriasis: Market Trends And Developments, 2015
    • 4.2.1. Biological Drugs In Psoriasis Treatment: A Brief Overview
    • 4.2.2. Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
    • 4.2.3. The Disadvantages Of Biologics In Psoriasis Treatment
  • 4.3. Psoriasis Drugs: Market Forecast 2015-2025
    • 4.3.1. Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 4.4. Leading Drugs Used In The Treatment Of Psoriasis
  • 4.5. Humira (adalimumab) - AbbVie
    • 4.5.1. Humira: Historical Sales Analysis, 2010-2014
    • 4.5.2. Humira: Sales Forecast 2015-2025
    • 4.5.3. Future Prospects For Biosimilar Versions Of Humira
  • 4.6. Stelara (ustekinumab) - Johnson & Johnson
    • 4.6.1. Stelara: Historical Sales Analysis, 2010-2014
    • 4.6.2. Stelara: Sales Forecast 2015-2025
    • 4.6.3. Intensifying Competition For Stelara
  • 4.7. Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
    • 4.7.1. Enbrel: Co-Promotions And Marketing Rights
    • 4.7.2. Enbrel: Historical Sales Analysis, 2008-2014
    • 4.7.3. Enbrel: Patent Expiries and Potential Competition, 2015-2025
    • 4.7.4. Enbrel: Sales Forecast 2015-2025
    • 4.7.5. Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
    • 4.7.6. Competition From Other Drugs
    • 4.7.7. Biosimilar Competition For Enbrel
  • 4.8. Remicade (infliximab) - Johnson & Johnson
    • 4.8.1. Remicade: Historical Sales Analysis, 2010-2014
    • 4.8.2. Remicade: Patent Expiries and Potential Competition, 2015-2025
    • 4.8.3. Remicade: Sales Forecast 2015-2025
  • 4.9. Daivobet (betamethasone/calcipotriene) - LEO Pharma
    • 4.9.1. Daivobet: Sales Forecast 2015-2025
    • 4.9.2. LEO Pharma's Life Cycle Management Of Daivobet
    • 4.9.3. Daivobet/Dovobet/Taclonex - Generic Competition
  • 4.10. Soriatane (acitretin) - GlaxoSmithKline
    • 4.10.1. Soriatane: Sales Forecast 2015-2025
  • 4.11. Other Psoriasis Drugs
    • 4.11.1. Cimzia (certolizumab) - UCB
    • 4.11.2. Cosentyx (secukinumab) - Novartis
    • 4.11.3. Otezla (apremilast) - Celgene
    • 4.11.4. Sorilux (calcipotriene foam) - GSK
    • 4.11.5. Other Psoriasis Drugs: Sales Forecast 2015-2025
  • 4.12. Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025

  • 5.1. Skin Infection Drugs: Abundant Growth Opportunities
    • 5.1.1. Leading Products In The Skin Infection Drugs Market, 2014
  • 5.2. Skin Infection Drugs: Market Forecast 2015-2025
    • 5.2.1. Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 5.3. Leading Drugs Used In The Treatment Of Skin Infections
  • 5.4. Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
    • 5.4.1. Acquisition By Merck & Co
    • 5.4.2. Generic Competition For Cubicin
    • 5.4.3. Cubicin: Sales Forecast 2015-2025
    • 5.4.4. Lifecycle Management Strategies For Cubicin
  • 5.5. Zyvox (linezolid) - Pfizer
    • 5.5.1. Zyvox: Historical Sales Analysis, 2010-2014
    • 5.5.2. Zyvox: Sales Forecast 2015-2025
    • 5.5.3. The Threats To Zyvox Sales From Competing New Drugs
  • 5.6. Valtrex (valaciclovir) - GSK
    • 5.6.1. Valtrex: Historical Sales Analysis, 2010-2014
    • 5.6.2. Valtrex: Sales Forecast 2015-2025
  • 5.7. Canesten (clotrimazole) - Bayer
    • 5.7.1. Canesten: Historical Sales Analysis, 2011-2014
    • 5.7.2. Canesten: Sales Forecast 2015-2025
  • 5.8. Lamisil (terbinafine) - Novartis
    • 5.8.1. Lamisil Patent Expiry
    • 5.8.2. Lamisil Sales Affected By Novartis Manufacturing Problems
    • 5.8.3. Lamisil: Sales Forecast 2015-2025
  • 5.9. Bactroban (mupirocin) - GSK
    • 5.9.1. Bactroban: Historical Sales Analysis, 2010-2013
    • 5.9.2. Bactroban: Sales Forecast 2015-2025
  • 5.10. Other Skin Infection Drugs
    • 5.10.1. Dalvance (dalbavancin) - Durata Therapeutics
    • 5.10.2. Jublia (efinaconazole) - Valeant
    • 5.10.3. Kerydin (tavaborole) - Anacor
    • 5.10.4. Sivextro (tedizolid) - Cubist Pharmaceuticals
    • 5.10.5. Zovirax (acyclovir) - Valeant/GSK
      • 5.10.5.1. Valeant Acquires Zovirax In US And Canada
      • 5.10.5.2. Mylan's Generic Zovirax And Actavis' Authorised Generic
    • 5.10.6. Other Skin Infection Drugs: Sales Forecast 2015-2025
  • 5.11. Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis And Forecast 2015-2025

  • 6.1. Acne Drugs: A Diversified Market
    • 6.1.1. Leading Products In The Acne Drugs Market, 2014
  • 6.2. Acne Drugs Market: Recent Trends and Developments
    • 6.2.1. The Rise Of Combination Therapies In Acne Treatment
    • 6.2.2. Oral Contraceptives In Treating Acne
    • 6.2.3. The Threat Of Generic Competition In The Acne Drugs Market
  • 6.3. Acne Drugs: Market Forecast 2015-2025
    • 6.3.1. Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 6.4. Leading Drugs In The Acne Drugs Market
  • 6.5. Solodyn (minocycline) - Valeant
    • 6.5.1. Solodyn: Sales Forecast 2015-2025
    • 6.5.2. Antitrust Action Over Solodyn Pay-For-Delay Deals
    • 6.5.3. Impax And Medicis Collaborating On Advanced Solodyn
    • 6.5.4. Medicis And Lupin Settle
  • 6.6. Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
    • 6.6.1. Epiduo: Sales Forecast 2015-2025
    • 6.6.2. Galderma Settlement Agreement Over Generic Epiduo
    • 6.6.3. Paediatric Approval For Epiduo
  • 6.7. Claravis (isotretinoin) - Teva
    • 6.7.1. Claravis: Sales Forecast 2015-2025
  • 6.8. Aczone (dapsone) - Allergan
    • 6.8.1. Aczone: Sales Forecast 2015-2025
  • 6.9. Differin (adapalene) - Galderma/ Nestlé Skin Health
    • 6.9.1. Recent Generic Competition To Differin
    • 6.9.2. Differin: Sales Forecast 2015-2025
    • 6.9.3. Federal Circuit Court Invalidates Differin Patents
  • 6.10. Absorica/Epuris (CIP-isotretinoin) - Cipher/ Sun Pharma
    • 6.10.1. Absorica/Epuris: Sales Forecast 2015-2025
  • 6.11. Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
    • 6.11.1. Valeant's Patent Settlement With Actavis Over Ziana
    • 6.11.2. Ziana: Sales Forecast 2015-2025
  • 6.12. Doryx (doxycycline) - Actavis/ Mayne Pharma
    • 6.12.1. Lifecycle Management Strategies For Doryx
    • 6.12.2. Divestment Agreement With Mayne Pharma
    • 6.12.3. Generic Competition For Doryx
    • 6.12.4. Doryx: Sales Forecast 2015-2025
  • 6.13. Other Acne Drugs
    • 6.13.1. Acanya (clindamycin/benzoyl peroxide) - Dow / Valeant
      • 6.13.1.1. Acanya: Financial Analysis
      • 6.13.1.2. Actavis Claims First-to-File Exclusivity for its Acanya ANDA
      • 6.13.1.3. Legal Battles Involving Dow/Valeant, Perrigo, And Watson
    • 6.13.2. Amnesteem (isotretinoin) - Mylan
      • 6.13.2.1. Amnesteem: Financial Analysis
    • 6.13.3. Diane (cyproterone/ethinyl estradiol) - Bayer
    • 6.13.4. Duac (clindamycin/benzoyl peroxide) - GlaxoSmithKline
      • 6.13.4.1. Duac: Financial Analysis
    • 6.13.5. Veltin (tretinoin/clindamycin) - GSK
    • 6.13.6. Other Acne Drugs: Sales Forecast 2015-2025
  • 6.14. Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025

  • 7.1. Dermatitis Drugs: High Generic Penetration
    • 7.1.1. Leading Products In The Dermatitis Drugs Market, 2014
  • 7.2. Dermatitis Drugs: Market Forecast 2015-2025
    • 7.2.1. Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 7.3. Leading Drugs In The Dermatitis Drugs Market
  • 7.4. Bepanthen (dexpanthenol)/ Bepanthol - Bayer
    • 7.4.1. Bepanthen: Sales Forecast 2015-2025
  • 7.5. Protopic (tacrolimus) - Astellas Pharma/ Roche
    • 7.5.1. Protopic Benefits From Expanded Indication
    • 7.5.2. Generic Competition For Protopic
    • 7.5.3. Protopic: Sales Forecast 2015-2025
  • 7.6. Elidel (pimecrolimus) - Meda Pharma/ Valeant
    • 7.6.1. Elidel: Sales Forecast 2015-2025
  • 7.7. Elocon (mometasone) - Merck & Co
    • 7.7.1. Elocon: Sales Forecast 2015-2025
  • 7.8. Other Dermatitis Drugs: Sales Forecast 2015-2025
  • 7.9. Dermatitis Drugs: Market Outlook

8. Leading National Markets For Dermatological Drugs, 2015-2025

  • 8.1. The Dermatological Drugs Market By Region
    • 8.1.1. The Global Distribution Of Dermatological Drugs In 2014
  • 8.2. Leading National Markets: Forecast 2015-2025
    • 8.2.1. Changing Market Shares By Region, 2015-2025
  • 8.3. Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
  • 8.4. United States: The Largest Dermatological Drugs Market
    • 8.4.1. The Impact Of An Expanding Medicare Coverage
    • 8.4.2. Legislative Environment Stimulating Biosimilars Market?
    • 8.4.3. US Dermatological Drugs Market: Market Forecast 2015-2025
  • 8.5. The EU5 Markets: Growth Expected In Each Country
    • 8.5.1. EU5 Dermatological Drugs Market: Market Forecast 2015-2025
      • 8.5.1.1. EU5 Markets: Changing Market Shares By Country, 2015-2025
    • 8.5.2. Germany
      • 8.5.2.1. German Dermatological Drugs Market: Market Forecast 2015-2025
    • 8.5.3. France
      • 8.5.3.1. French Dermatological Drugs Market Forecast 2015-2025
    • 8.5.4. UK
      • 8.5.4.1. UK Dermatological Drugs Market Forecast 2015-2025
    • 8.5.5. Italy
      • 8.5.5.1. Italian Dermatological Drugs Market Forecast 2015-2025
    • 8.5.6. Spain
      • 8.5.6.1. Spanish Dermatological Drugs Market Forecast 2015-2025
  • 8.6. Japan
    • 8.6.1. The Cost Of Treatment In Japan
    • 8.6.2. Japanese Pharmaceutical Industry Regulatory Reform
    • 8.6.3. Japanese Dermatological Drugs Market Forecast 2015-2025
  • 8.7. China
    • 8.7.1. Expansion Of Healthcare Coverage And Reimbursement In China
    • 8.7.2. Improving Public Perception Of Dermatology In China
    • 8.7.3. Price Controls And The Anhui Model
    • 8.7.4. Chinese Dermatological Drugs Market Forecast 2015-2025
  • 8.8. India
    • 8.8.1. The Effects Of The Drug Prices Control Order Of 2013
    • 8.8.2. India's Expansion Of Healthcare Provision
    • 8.8.3. Indian Dermatological Drugs Market Forecast 2015-2025
  • 8.9. Brazil
    • 8.9.1. The Growth In Brazil's Healthcare Landscape
    • 8.9.2. Clearer Access To Medicines In Brazil
    • 8.9.3. Brazilian Dermatological Drugs Market Forecast 2015-2025
  • 8.10. Russia
    • 8.10.1. Pharma2020 Strategy - Healthcare And Industry Reform
    • 8.10.2. Russian Dermatological Drugs Market Forecast 2015-2025
  • 8.11. Mexico
    • 8.11.1. Seguro Popular: Mexican Healthcare Reform
    • 8.11.2. Are Multinationals Waking Up To Mexico's Potential?
    • 8.11.3. Mexican Dermatological Drugs Market Forecast 2015-2025
  • 8.12. Rest of the World
    • 8.12.1. The Rest of the World Dermatological Drugs Market Forecast 2015-2025

9. Leading Companies In The Dermatological Drugs Market, 2015-2025

  • 9.1. Dermatological Drugs - A Rapidly Consolidating Market
  • 9.2. Galderma (Nestle Skin Health S.A.)
    • 9.2.1. Galderma: Dermatological Drugs Portfolio, 2015
    • 9.2.2. Galderma: Recent Developments
      • 9.2.2.1. Nestlé's Acquisition Of Galderma
      • 9.2.2.2. Approval Of Soolantra For Rosacea
      • 9.2.2.3. Mirvaso Launched For Rosacea
  • 9.3. Johnson & Johnson
    • 9.3.1. Johnson & Johnson: Dermatological Drugs Portfolio, 2015
    • 9.3.2. Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025
    • 9.3.3. Johnson And Johnson: Dermatological Drug Development Efforts, 2015
  • 9.4. AbbVie
    • 9.4.1. AbbVie: Dermatological Drugs Portfolio, 2015
    • 9.4.2. AbbVie Dermatological Drugs Sales Forecast 2015-2025
    • 9.4.3. AbbVie: Dermatological Drugs Development Pipeline, 2015
  • 9.4.3.1. BT-061 (tregalizumab) For The Treatment Of Psoriasis
  • 9.5. GlaxoSmithKline (GSK)
    • 9.5.1. GSK: Dermatological Drugs Portfolio, 2015
    • 9.5.2. GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
    • 9.5.3. GlaxoSmithKline (GSK): Recent Developments
  • 9.5.3.1. Business Restructuring Arrangements With Novartis
  • 9.5.3.2. Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
    • 9.5.4. GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
  • 9.6. Pfizer
    • 9.6.1. Pfizer: Dermatological Drugs Portfolio, 2015
    • 9.6.2. Pfizer Dermatological Drugs Sales Forecast 2015-2025
    • 9.6.3. Pfizer: Dermatological Drugs Development Pipeline, 2015
  • 9.7. LEO Pharma
    • 9.7.1. LEO Pharma: Dermatological Drugs Portfolio, 2015
    • 9.7.2. LEO Pharma Dermatological Drugs Sales Forecast 2015-2025

10. Dermatological Drugs: Research And Development Pipeline, 2015-2025

  • 10.1. Innovative Products Currently In Development Will Drive Growth
    • 10.1.1. New Technology In R&D Pipeline Activities
      • 10.1.1.1. Reformulation
      • 10.1.1.2. Combination Treatments
      • 10.1.1.3. New Mechanisms And Drug Delivery Technologies
      • 10.1.1.4. Potential Market Entrants
  • 10.2. Psoriasis Drugs Development Pipeline, 2015
    • 10.2.1. Psoriasis Drugs In Phase 3 Development
      • 10.2.1.1. 000-0551 Lotion (halobetasol) - Therapeutics, Inc
      • 10.2.1.2. AMG 827 (brodalumab) - AstraZeneca/ Amgen
      • 10.2.1.3. CF101 (IB-MECA) - Can-Fite BioPharma
      • 10.2.1.4. CNTO 1959 (guselkumab) - MorphoSys/ Janssen
      • 10.2.1.5. LAS41008 (dimethyl fumarate) - Almirall
      • 10.2.1.6. LEO 90100 - LEO Pharma
      • 10.2.1.7. LY2439821 (ixekizumab) - Eli Lilly
      • 10.2.1.8. MK-3222/SCH 900222 (tildrakizumab) - Merck
      • 10.2.1.9. STF 115469 (calcipotriene foam) - GSK
      • 10.2.1.10. Xeljanz (tofacitinib) - Pfizer
    • 10.2.2. Psoriasis Drugs In Phase 2 Development
      • 10.2.2.1. AN2728 (PDE-4 inhibitor) - Anacor Pharmaceuticals
      • 10.2.2.2. CT327 (TrkA inhibitor) - Creabilis Therapeutics
      • 10.2.2.3. ASP015K (JAK inhibitor) - Astellas Pharma
      • 10.2.2.4. Jakavi/Jakafi (ruxolitinib) - Incyte/ Novartis
      • 10.2.2.5. LY3009104 (baricitinib) - Incyte/ Eli Lilly
      • 10.2.2.6. PH-10 (Rose Bengal) - Provectus Biopharmaceuticals
    • 10.2.3. Psoriasis Drugs In Phase 1 And Pre-clinical Development
  • 10.3. Skin Infection Drugs Development Pipeline, 2015
    • 10.3.1. Drugs In Phase 3 Development For Skin Infections
      • 10.3.1.1. Delafloxacin (delafloxacin) - Melinta Pharmaceuticals
      • 10.3.1.2. NB-001 - NanoBio Corporation
      • 10.3.1.3. Orbactiv/ Nuvocid (oritavancin) - The Medicines Company
      • 10.3.1.4. Luliconazole - Topica Pharmaceuticals
    • 10.3.2. Drugs In Phase 2 Development For Skin Infections
    • 10.3.3. Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
  • 10.4. Acne Drugs Development Pipeline, 2015
    • 10.4.1. Drugs In Phase 3 Development For Acne
      • 10.4.1.1. Duac low dose (clindamycin/ benzoyl peroxide) - GlaxoSmithKline
      • 10.4.1.2. Visonac (photodynamic therapy) - Photocure
    • 10.4.2. Drugs In Phase 2 Development For Acne
    • 10.4.3. Drugs In Phase 1 And Pre-clinical Development For Acne
    • 10.4.4. A Possible Vaccine For Acne
  • 10.5. Dermatitis Drugs Development Pipeline, 2015
    • 10.5.1. Drugs In Phase 3 Development For Dermatitis
      • 10.5.1.1. Toctino (alitretinoin) - GSK
      • 10.5.1.2. Dermadexin and Pruridexin (P3CGM) - Cipher Pharmaceuticals
      • 10.5.1.3. Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre
      • 10.5.1.4. REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi
      • 10.5.1.5. Soriatane (acitretin) - InnovaDerm/Tribute Pharmaceuticals
    • 10.5.2. Drugs In Phase 2 Development For Dermatitis
    • 10.5.3. Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
  • 10.6. Other Dermatological Drugs Development Pipeline, 2015
    • 10.6.1. Other Dermatological Drugs: Filed or Recently Launched
      • 10.6.1.1. Actikerall (fluorouracil/salicylic acid) - Almirall
      • 10.6.1.2. Ameluz (5-ALA photodynamic therapy) - Biofrontera
      • 10.6.1.3. Keytruda (MK-3475, Pembrolizumab) - Merck
      • 10.6.1.4. Mirvaso (brimonidine) - Galderma
      • 10.6.1.5. Picato (ingenol mebutate) - LEO Pharma
      • 10.6.1.6. Xolair (omalizumab) - Novartis/ Roche
    • 10.6.2. Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
      • 10.6.2.1. Atralin (tretinoin) - Valeant
      • 10.6.2.2. BMS-936558 (nivolumab) - Bristol-Myers Squibb
      • 10.6.2.3. CD5024 (ivermectin) - Galderma
      • 10.6.2.4. Latisse (bimatoprost) - Allergan (Actavis)
      • 10.6.2.5. LEE011, LGX818, and MEK162 - Novartis
      • 10.6.2.6. Oleogel-S10 (triterpene extract) - Birken AG
      • 10.6.2.7. PV-10 (Rose Bengal) - Provectus Pharmaceuticals
      • 10.6.2.8. SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology
      • 10.6.2.9. TVEC (talimogene laherparepvec) - Amgen
    • 10.6.3. Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
    • 10.6.4. Other Dermatological Drugs: Phase 1 and Preclinical Pipeline

11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025

  • 11.1. Market Factors Influencing Dermatological Drugs
  • 11.2. SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
    • 11.2.1. Strengths
      • 11.2.1.1. The High Unmet Clinical Need In Dermatology
      • 11.2.1.2. A Healthy Pipeline Of Development-Stage Products
      • 11.2.1.3. Strong Industry-Physician Relationships
    • 11.2.2. Weaknesses
      • 11.2.2.1. Limited Efficacy And Adverse Effects May Impact Product Uptake
      • 11.2.2.2. Patient Adherence - A Major Challenge To Treatment Design
      • 11.2.2.3. Impending Patent Expiries And The Challenges Posed By Generic Competition
    • 11.2.3. Opportunities
      • 11.2.3.1. The High-Growth Sectors In Dermatology
      • 11.2.3.2. Personalised Dermatology: Technological Advances In Genomics
      • 11.2.3.3. Advances In Topical Drug Delivery Methods Offers Product Differentiation
      • 11.2.3.4. Consolidation Within Dermatology - Opportunity For Synergistic Growth?
    • 11.2.4. Threats
      • 11.2.4.1. Uncertain Surrounding Reimbursement And Payment Approvals
      • 11.2.4.2. The Rising Cost Of Research And Development
      • 11.2.4.3. Downward Pressures On Drug Prices
  • 11.3. Porter's Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
    • 11.3.1. Threat Of New Entrants
    • 11.3.2. Threat Of Substitutes
    • 11.3.3. Rivalry Among Competitors
    • 11.3.4. Power Of Buyers
    • 11.3.5. Power Of Suppliers

12. Expert Opinions from Our Primary Research

  • 12.1. Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
    • 12.1.1. Visonac As An Innovative First-In-Class Treatment
    • 12.1.2. Photocure's Development Plans For Visonac
    • 12.1.3. Commercialisation Strategy For Visonac
    • 12.1.4. On The Geographical Reach Of Acne Treatments
    • 12.1.5. The Key Unmet Needs Within Patient Populations For Acne
    • 12.1.6. The Key Forces Driving And Restraining The Development Of Acne Therapies
    • 12.1.7. On The Current Development Pipeline For Acne Therapies
    • 12.1.8. On Photocure's Plans For Future Growth
    • 12.1.9. Future Prospects For The Acne Treatments Market

13. Conclusions

  • 13.1. Overview Of Current Market Conditions And Market Forecast, 2014-2025
  • 13.2. Leading Sectors In Dermatological Drugs In 2014
  • 13.3. Leading Regions In The Dermatological Drugs Market In 2014
  • 13.4. Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
  • 13.5. What Does The Future Hold For Dermatological Drugs?

List of Tables

  • Table 1.1: Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025 (Redacted Data)
  • Table 2.1: Clinical Trial Phases, 2015
  • Table 3.1: The Global Dermatological Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
  • Table 3.2: The Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025
  • Table 3.3: The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
  • Table 3.4: The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
  • Table 4.1: Top Drugs In The Psoriasis Drugs Market: Revenue ($m) and Market Shares (%), 2014
  • Table 4.2: Psoriasis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 4.3: The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 4.4: Humira: Historical Sales ($m, AGR%), 2010-2014
  • Table 4.5: Humira: AbbVie Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.6: Stelara: Historical Sales ($m, AGR%), 2010-2014
  • Table 4.7: Stelara: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.8: Enbrel: Historical Sales ($m,bn Yen, AGR%) by Company, 2008-2014
  • Table 4.9: Enbrel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.10: Remicade: Historical Sales ($m, bn Yen, AGR%), 2010-2014
  • Table 4.11: Remicade: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.12: Daivobet: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.13: Soriatane: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.14: Other Psoriasis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.1: Top Drugs In The Skin Infection Drugs Market: Revenue ($m) and Market Share (%), 2014
  • Table 5.2: Skin Infection Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 5.3: The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 5.4: Cubicin: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.5: Zyvox: Historical Sales ($m, AGR%), 2010-2014
  • Table 5.6: Zyvox: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.7: Valtrex: Historical Sales ($m, £m, AGR%), 2010-2014
  • Table 5.8: Valtrex: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.9: Canesten: Historical Sales ($m, Euros, AGR%), 2011-2014
  • Table 5.10: Canesten: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.11: Lamisil: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.12: Bactroban: Historical Sales ($m, Euros, AGR%), 2010-2013
  • Table 5.13: Bactroban: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.14: Other Skin Infection Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.1: Top Drugs In The Acne Drugs Market: Revenue ($m) and Market Share (%), 2014
  • Table 6.2: Acne Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 6.3: The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 6.4: Solodyn (Valeant): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.5: Epiduo (Galderma/ Nestlé): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.6: Claravis (Teva): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.7: Aczone (Allergan): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.8: Differin (Galderma/ Nestlé): Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.9: Absorica/Epuris: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.10: Ziana: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.11: Doryx: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.12: Other Acne Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.1: Top Drugs In The Dermatitis Drugs Market: Revenue ($m) and Market Share (%), 2014
  • Table 7.2: Dermatitis Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 7.3: The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 7.4: Bepanthen/Bepanthol: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.5: Protopic: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.6: Elidel: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.7: Elocon: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.8: Other Dermatitis Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.1: The Global Dermatological Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
  • Table 8.2: Global Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
  • Table 8.3: The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
  • Table 8.4: The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
  • Table 8.5: The US Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.6: US Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.7: The EU5 Dermatological Drugs Market: Revenue ($m), and Market Share (%) by Country, 2014
  • Table 8.8: The EU5 Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.9: The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
  • Table 8.10: The German Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.11: The German Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.12: The French Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.13: The French Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.14: The UK Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.15: The UK Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.16: The Italian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.17: The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.18: The Spanish Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.19: The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.20: The Japanese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.21: The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.22: The Chinese Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.23: The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.24: The Indian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.25: The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.26: The Brazilian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.27: The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.28: The Russian Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.29: The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.30: The Mexican Dermatological Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.31: The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.32: The Rest of the World Dermatological Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
  • Table 8.33: The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.1: Galderma: Company Overview, 2013 And 2014
  • Table 9.2: Johnson & Johnson: Company Overview, 2014
  • Table 9.3: Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.4: AbbVie: Company Overview, 2014
  • Table 9.5: AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.6: GlaxoSmithKline: Company Overview, 2014
  • Table 9.7: GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.8: GlaxoSmithKline: Dermatological Drugs Pipeline, 2015
  • Table 9.9: Pfizer: Company Overview, 2014
  • Table 9.10: Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.11: LEO Pharma: Company Overview, 2014
  • Table 9.12: LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 10.1: Psoriasis Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.2: Psoriasis Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.3: Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2015
  • Table 10.4: Skin Infections Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.5: Skin Infections Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.6: Acne Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.7: Acne Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.8: Dermatitis Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.9: Dermatitis Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.10: Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2015
  • Table 10.11: Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.12: Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.13: Other Dermatological Drugs Pipeline: Phase 1 and Preclinical Drugs, 2015
  • Table 11.1: SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025
  • Table 13.1: Global Dermatological Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
  • Table 13.2: The Global Dermatological Drugs Market: Market Size ($m) and Market Shares (%) by Sector, 2014
  • Table 13.3: The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025
  • Table 13.4: The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025

List of Figures

  • Figure 1.1: Global Dermatological Drugs Market: Market Sectors, 2015
  • Figure 1.2: Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Altered Data)
  • Figure 2.1: Anatomy of the Human Skin
  • Figure 3.1: The Global Dermatological Drugs Market: Revenue ($m) by Sector, 2014
  • Figure 3.2: The Global Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 3.3: The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
  • Figure 3.4: The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
  • Figure 3.5: The Global Dermatological Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
  • Figure 3.6: The Global Dermatological Drugs Market: Market Share (%) by Sector, 2014
  • Figure 3.7: The Global Dermatological Drugs Market: Market Share (%) by Sector, 2019
  • Figure 3.8: The Global Dermatological Drugs Market: Market Share (%) by Sector, 2025
  • Figure 4.1: Top Drugs In The Psoriasis Drugs Market: Revenue ($m), 2014
  • Figure 4.2: Psoriasis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 4.3: The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 4.4: The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 4.5: The Global Psoriasis Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 4.6: Humira: Historical Sales ($m, AGR%), 2010-2014
  • Figure 4.7: Humira: AbbVie Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.8: Stelara: Historical Sales ($m, AGR%), 2010-2014
  • Figure 4.9: Stelara: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.10: Enbrel: Historical Sales ($m) by Company, 2008-2014
  • Figure 4.11: Enbrel: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.12: Remicade: Historical Sales ($m, AGR%), 2010-2014
  • Figure 4.13: Remicade: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.14: Daivobet: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.15: Soriatane: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.16: Other Psoriasis Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.1: Top Drugs In The Skin Infection Drugs Market: Revenue ($m), 2014
  • Figure 5.2: Skin Infection Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 5.3: The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 5.4: The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 5.5: The Global Skin Infection Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 5.6: Cubicin: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.7: Zyvox: Historical Sales ($m, AGR%), 2010-2014
  • Figure 5.8: Zyvox: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.9: Valtrex: Historical Sales ($m, AGR%), 2010-2014
  • Figure 5.10: Valtrex: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.11: Canesten: Historical Sales ($m, AGR%), 2011-2014
  • Figure 5.12: Canesten: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.13: Lamisil: Novartis Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.14: Bactroban: Historical Sales ($m, AGR%), 2010-2013
  • Figure 5.15: Bactroban: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.16: Other Skin Infection Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.1: Top Drugs In The Acne Drugs Market: Revenue ($m), 2014
  • Figure 6.2: Acne Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 6.3: The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 6.4: The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 6.5: The Global Acne Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 6.6: Solodyn (Valeant): Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.7: Epiduo (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.8: Claravis (Teva): Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.9: Aczone (Allergan): Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.10: Differin (Galderma/ Nestlé): Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.11: Absorica/Epuris: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.12: Ziana: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.13: Doryx: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.14: Other Acne Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.1: Top Drugs In The Dermatitis Drugs Market: Revenue ($m), 2014
  • Figure 7.2: Dermatitis Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 7.3: The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 7.4: The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 7.5: The Global Dermatitis Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 7.6: Bepanthen/Bepanthol: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.7: Protopic: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.8: Elidel: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.9: Elocon: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.10: Other Dermatitis Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 8.1: The Global Dermatological Drugs Market: Market Size ($m) by Region, 2014
  • Figure 8.2: US, EU5, and Japan Dermatological Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.3: Brazil, Russia, India, China, and Mexico Dermatological Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.4: The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2019
  • Figure 8.5: The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2019-2025
  • Figure 8.6: The Global Dermatological Drugs Market Forecast: CAGR (%) by Region, 2014-2025
  • Figure 8.7: The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2014
  • Figure 8.8: The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2019
  • Figure 8.9: The Global Dermatological Drugs Market Forecast: Market Share (%) by Region, 2025
  • Figure 8.10: US Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.11: The EU5 Dermatological Drugs Market: Revenue ($m) by Country, 2014
  • Figure 8.12: Germany, France, UK, Italy, and Spain Dermatological Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.13: The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2014
  • Figure 8.14: The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2019
  • Figure 8.15: The EU5 Dermatological Drugs Market: Market Share (%) by Country, 2025
  • Figure 8.16: The German Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.17: The French Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.18: The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.19: The Italian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.20: The Spanish Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.21: The Japanese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.22: The Chinese Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.23: The Indian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.24: The Brazilian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.25: The Russian Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.26: The Mexican Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.27: The Rest of the World Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 9.1: Johnson & Johnson: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.2: AbbVie: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.3: GlaxoSmithKline: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.4: Pfizer: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.5: LEO Pharma: Dermatological Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 11.1: Porter's Five Force Analysis of the Dermatological Drugs Market, 2015
  • Figure 13.1: Global Dermatological Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
  • Figure 13.2: The Global Dermatological Drugs Market: Market Size ($m) by Sector, 2014
  • Figure 13.3: The Global Dermatological Drugs Market: Market Forecast ($m) by Region, 2014-2025
  • Figure 13.4: The Global Dermatological Drugs Market: Market Forecast ($m) by Sector, 2014, 2018, 2021, 2025

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • AbGenomics
  • Actavis
  • Actelion
  • AET BioTech
  • Affinium (DebioPharm Group)
  • AiCuris
  • Alembic Pharmaceuticals
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor Pharmaceuticals
  • AndroScience Group
  • AnGes M G
  • Anterios
  • Apeiron Biologics
  • Ascend Therapeutics
  • Astellas Pharma
  • Astion Pharma
  • AstraZeneca
  • Asubio Pharma (Daiichi Sankyo)
  • Atrix Laboratories
  • Aurobindo Pharma
  • Ausio Pharmaceuticals
  • Barr Laboratories
  • Basilea Pharmaceutica
  • Bayer
  • Boehringer Ingelheim
  • Berg Pharma
  • Bertek Pharmaceuticals
  • Biocon
  • Biofrontera
  • Biogen Idec
  • Biotest AG
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Birken AG
  • Braintree Laboratories
  • Bristol-Myers Squibb
  • Cadila Healthcare
  • Can-Fite Biopharma
  • Cardinal Health
  • Celgene
  • Cellceutix
  • Celltech
  • Celltrion
  • Celsus Therapeutics
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Circassia
  • CollaGenex
  • Compañía Internacional de Comercio
  • Convoy Therapeutics
  • Cosmo Pharmaceuticals
  • Creabilis Therapeutics
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • DAVA Pharmaceuticals
  • Delenex Therapeutics
  • Dermira Inc
  • Dow Pharmaceutical Sciences
  • Dr Reddy's Laboratories
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • Elorac
  • Foamix
  • Fortuderm
  • Forward Pharma
  • Fougera Pharmaceuticals (Sandoz)
  • Fujifilm
  • Fujisawa Healthcare
  • Furiex Pharmaceuticals
  • G&E Herbal Biotechnology
  • G&W Laboratories
  • Galderma (Nestle)
  • Gene Signal
  • Genentech (Roche)
  • Genpharm
  • Genzyme (Sanofi)
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Grupo Imperial
  • Hanwha Pharma
  • Heritage Pharmaceuticals
  • Hospira
  • Idera Pharmaceuticals
  • Immune Response BioPharma Inc
  • Immunex
  • Impax Laboratories
  • Incyte
  • Innovaderm Research
  • Instituto Terapeutico Delta Ltda
  • Intrepid Therapeutics
  • Janssen Biotech
  • Johnson & Johnson
  • Kosei
  • Kyowa Hakko Kirin
  • L'Oreal
  • Laboratorios Kendrick
  • LEO Foundation
  • LEO Pharma
  • Lupin Pharmaceuticals
  • Maruho
  • Meda Pharma
  • Medicis (Valeant)
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Moleculin
  • MorphoSys
  • Mycenax Biotech
  • Mylan
  • Nabriva Therapeutics
  • NanoBio Corporation
  • Nestle
  • NovaBay
  • Novartis
  • OpthaliX
  • Par Pharmaceutical
  • Paratek Pharmaceuticals
  • Peplin (LEO Pharma)
  • Perrigo
  • Pfizer
  • Pharmacia (Pfizer)
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Pliva Hrvatska
  • Precision Dermatology
  • Provectus Biopharmaceuticals
  • Q-Med
  • Ranbaxy
  • Regeneron
  • Roche
  • Rochester Drug Co-operative
  • Roxane Laboratories
  • S.A.P.I. de C.V. (CISCA)
  • Samsung Bioepis
  • Sandoz (Novartis)
  • Sanofi
  • Shape Pharmaceuticals
  • Shionogi & Co
  • Sidmak Laboratories
  • Sol-Gel Technologies
  • Stiefel Laboratories (GSK)
  • Sun Pharmaceuticals
  • Sunovion Pharmaceuticals
  • Switch Biotech
  • Taisho Pharmaceuticals
  • Takeda
  • Targanta Therapeutics
  • Taro Pharmaceuticals
  • Tecnofarma
  • Telormedix
  • Teva
  • The Medicines Company
  • Therapeutics Inc
  • Theravance
  • Tolmar Inc
  • Topica Pharmaceuticals
  • Trius Therapeutics
  • UCB Pharma
  • Valeant Pharmaceuticals
  • Vatera Healthcare Partners
  • VBL Therapeutics
  • Vedara Therapeutics
  • ViiV Healthcare (GSK)
  • ViroBay
  • Vitacilina Corporation of America (VitaCorp)
  • Warner Chilcott (Actavis)
  • Welichem Biotech
  • Wolters Kluwer
  • Wyeth (Pfizer)
  • XBiotech
  • XenoPort
  • Xoma

Organisations Mentioned In The Report

  • Brazilian Society of Dermatology
  • British Association of Dermatologists
  • Chinese Society of Dermatology
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Administration (FDA) [US]
  • Health Canada
  • National Development and Reform Commission (NDRC) [China]
  • National Health Services (NHS) [UK]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • National Institutes of Health [US]
  • National Pharmaceutical Pricing Authority (NPPA) [China]
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Servicio Sanitario Nazionale (SSN) [US]
  • St. Luke's-Roosevelt Hospital Center, New York [US]
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • United States District Court for the District of New Jersey
  • University of California, San Diego [US]
  • University of Michigan [US]
  • US Patent Office
Back to Top